Terms: = Bone cancer AND IKZF1, LyF-1, 10320, ENSG00000185811, Q13422, Hs_54452, hIk-1, ZNFN1A1, IKAROS
65 results:
1. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
2. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Bastian L; Beder T; Barz MJ; Bendig S; Bartsch L; Walter W; Wolgast N; Brändl B; Rohrandt C; Hansen BT; Hartmann AM; Iben K; Das Gupta D; Denker M; Zimmermann J; Wittig M; Chitadze G; Neumann M; Schneller F; Fiedler W; Steffen B; Stelljes M; Faul C; Schwartz S; Müller FJ; Cario G; Harder L; Haferlach C; Pfeifer H; Gökbuget N; Brüggemann M; Baldus CD
Blood; 2024 Apr; 143(14):1391-1398. PubMed ID: 38153913
[TBL] [Abstract] [Full Text] [Related]
3. Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the bone Marrow Pathology Group.
Kirtek T; Chen W; Laczko D; Bagg A; Koduru P; Foucar K; Venable E; Nichols M; Rogers HJ; Tam W; Orazi A; Hsi ED; Hasserjian RP; Wang SA; Arber DA; Weinberg OK
Leuk Res; 2023 Jul; 130():107309. PubMed ID: 37210875
[TBL] [Abstract] [Full Text] [Related]
4. Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.
Venn NC; Huang L; Hovorková L; Muskovic W; Wong M; Law T; Heatley SL; Khaw SL; Revesz T; Dalla Pozza L; Shaw PJ; Fraser C; Moore AS; Cross S; Bendak K; Norris MD; Henderson MJ; White DL; Cowley MJ; Trahair TN; Zuna J; Sutton R
Br J Cancer; 2022 Sep; 127(5):908-915. PubMed ID: 35650277
[TBL] [Abstract] [Full Text] [Related]
5. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.
Eckardt JN; Stölzel F; Kunadt D; Röllig C; Stasik S; Wagenführ L; Jöhrens K; Kuithan F; Krämer A; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause SW; Herbst R; Hänel M; Hanoun M; Kaiser U; Kaufmann M; Rácil Z; Mayer J; Kroschinsky F; Berdel WE; Ehninger G; Serve H; Müller-Tidow C; Platzbecker U; Baldus CD; Schetelig J; Bornhäuser M; Thiede C; Middeke JM
J Hematol Oncol; 2022 May; 15(1):60. PubMed ID: 35562747
[TBL] [Abstract] [Full Text] [Related]
6. [Clinical characteristics and therapeutic effect of TP53 variant in patients with acute leukemia].
Mi R; Guo Z; Liu W; Hu J; Fan R; Chen L; Liu J; Wei X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Oct; 38(10):955-960. PubMed ID: 34625931
[TBL] [Abstract] [Full Text] [Related]
7. β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection.
Guenther C; Faisal I; Fusciello M; Sokolova M; Harjunpää H; Ilander M; Tallberg R; Vartiainen MK; Alon R; Gonzalez-Granado JM; Cerullo V; Fagerholm SC
Cancer Immunol Res; 2021 Nov; 9(11):1354-1369. PubMed ID: 34561280
[TBL] [Abstract] [Full Text] [Related]
8. Pathogenic germline
Brodie SA; Khincha PP; Giri N; Bouk AJ; Steinberg M; Dai J; Jessop L; Donovan FX; Chandrasekharappa SC; de Andrade KC; Maric I; Ellis SR; Mirabello L; Alter BP; Savage SA
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34162668
[No Abstract] [Full Text] [Related]
9. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract] [Full Text] [Related]
10. The ikzf1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract] [Full Text] [Related]
11. RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with ikzf1 deletions.
Huang YJ; Liu HC; Jaing TH; Wu KH; Wang SC; Yen HJ; Hsiao CC; Chen SH; Lin PC; Yeh TC; Sheen JM; Chen YC; Chang TK; Huang FL; Chao YH; Hou JY; Yang CP; Lin TH; Shih LY
Pediatr Blood Cancer; 2021 Apr; 68(4):e28899. PubMed ID: 33522704
[TBL] [Abstract] [Full Text] [Related]
12. Frequency and Correlation of Common Genes Copy Number Alterations in Childhood Acute Lymphoblastic Leukemia with Prognosis.
Hosein Pour Feizi A; Zeinali S; Toporski J; Sheervalilou R; Mehranfar S
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3493-3500. PubMed ID: 33369444
[TBL] [Abstract] [Full Text] [Related]
13. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring ikzf1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
Giebel S; Labopin M; Socié G; Beauvais D; Klein S; Wagner-Drouet EM; Blaise D; Nguyen-Quoc S; Bourhis JH; Thiebaut A; Labussière-Wallet H; Charbonnier A; Berceanu A; Diez-Martin JL; Fegueux N; Esteve J; Nagler A; Mohty M
Bone Marrow Transplant; 2021 May; 56(5):1047-1055. PubMed ID: 33235351
[TBL] [Abstract] [Full Text] [Related]
14. Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of ikzf1-IRF4-MYC Axis.
Murugesan A; Lassalle-Claux G; Hogan L; Vaillancourt E; Selka A; Luiker K; Kim MJ; Touaibia M; Reiman T
J Nat Prod; 2020 Dec; 83(12):3526-3535. PubMed ID: 33210536
[TBL] [Abstract] [Full Text] [Related]
15. Old and new generation immunomodulatory drugs in multiple myeloma.
Derudas D; Capraro F; Martinelli G; Cerchione C
Panminerva Med; 2020 Dec; 62(4):207-219. PubMed ID: 32955182
[TBL] [Abstract] [Full Text] [Related]
16. Germline ikaros dimerization haploinsufficiency causes hematologic cytopenias and malignancies.
Kuehn HS; Niemela JE; Stoddard J; Mannurita SC; Shahin T; Goel S; Hintermeyer M; Heredia RJ; Garofalo M; Lucas L; Singh S; Tondo A; Jacobs Z; Gahl WA; Latour S; Verbsky J; Routes J; Cunningham-Rundles C; Boztug K; Gambineri E; Fleisher TA; Chandrakasan S; Rosenzweig SD
Blood; 2021 Jan; 137(3):349-363. PubMed ID: 32845957
[TBL] [Abstract] [Full Text] [Related]
17. Hereditary Predisposition to Hematopoietic Neoplasms: When Bloodline Matters for Blood cancers.
Mangaonkar AA; Patnaik MM
Mayo Clin Proc; 2020 Jul; 95(7):1482-1498. PubMed ID: 32571604
[TBL] [Abstract] [Full Text] [Related]
18. Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro.
He X; Dou A; Feng S; Roman-Rivera A; Hawkins C; Lawley L; Zhang J; Wunderlich M; Mizukawa B; Halene S; Patel A; Fang J
Exp Hematol; 2020 Jun; 86():21-27.e2. PubMed ID: 32437909
[TBL] [Abstract] [Full Text] [Related]
19. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
Hideshima T; Ogiya D; Liu J; Harada T; Kurata K; Bae J; Massefski W; Anderson KC
Leukemia; 2021 Jan; 35(1):177-188. PubMed ID: 32238854
[TBL] [Abstract] [Full Text] [Related]
20. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
Zeidner JF; Knaus HA; Zeidan AM; Blackford AL; Montiel-Esparza R; Hackl H; Prince GT; Gondek LP; Ghiaur G; Showel MM; DeZern AE; Pratz KW; Douglas Smith B; Levis MJ; Gore S; Coombs CC; Foster MC; Streicher H; Karp JE; Luznik L; Gojo I
Leukemia; 2020 Jun; 34(6):1563-1576. PubMed ID: 31900407
[TBL] [Abstract] [Full Text] [Related]
[Next]
